Logistics and cost issue. Much cheaper to just get them from labs in China. Which based on those pending trials in China there are several manufacturers. Also any revenue from most of the things discussed on here lately would be years away. We need to focus on funding, rolling out or selling off diagnostics, acquisitions, partnerships, anything that would raise shareholder value in year 2020. The lower this gets the harder it is to go back up. If stem cells are gonna flop for the near term we need another source of revenue to at least fund day to day operations. Gotta get diagnostic revenue rolling. No more shares need to be issued. Float is great for nasdaq for volume but awful for the otc.
News 
Market Data 
Discover 
